Maryland company wins FDA fast-track status for superbug drug

Rockville-based Synthetic Biologics Inc. received fast-track status from the Food and Drug Administration for a drug candidate that might prevent one of the most common health care-associated infections in the U.S. Clostridium difficile, often referred to as C. diff, sickens more than 450,000 patients in the U.S. every year and causes $1.5 billion in additional health care costs annually. The drug candidate SYN-004 is an oral enzyme designed to protect the gut microbiome against C. diff and the…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news